A man in his late forties had been dealing with a torn rotator cuff for eight months. He had done physical therapy, taken anti-inflammatories, and was looking at surgery as the next step. Someone in his training group mentioned BPC-157, a peptide that had been circulating in athletic and functional medicine circles for its reported healing properties. His sports medicine provider had never heard of it. His orthopedic surgeon said it was unproven.
Three months later, having sourced the peptide through a regulated compounding pharmacy and worked with a provider who understood how to use it, his range of motion had recovered substantially and surgery was no longer on the table. His experience is not unique. But it illustrates a broader problem: the medical system’s unfamiliarity with peptide therapies is leaving effective treatments on the shelf for patients who could benefit from them.
What Peptides Actually Are
Peptides are short-chain amino acids, the same building blocks that make up proteins. While proteins can be hundreds or thousands of amino acids long, peptides are typically between 2 and 50. Their small size and specific sequences allow them to act as highly targeted biological messengers, binding to specific receptors and triggering precise cellular responses.
What makes this category interesting from a therapeutic standpoint is how specific that targeting can be. A peptide can stimulate tissue repair in tendons without broadly elevating growth hormone. Another can activate T-cell production in the immune system without triggering a generalized immune response. Another can reduce anxiety via a pathway that does not involve the sedative mechanisms of pharmaceutical anxiolytics.
The medical community is more familiar with peptides than it realizes. GLP-1 receptor agonists, including semaglutide and tirzepatide, are peptides. They have been used in millions of patients for diabetes and weight management. The pharmacological category is not novel. What is less familiar is the broader range of peptides that do not come from pharmaceutical companies because they cannot be patented.
The Pharmaceutical Patent Problem
Here is why most peptides are not part of conventional medicine: natural peptides cannot be patented. A pharmaceutical company cannot obtain exclusive rights to a naturally occurring compound, which means there is no pathway to recoup the billions spent on clinical trials through decades of exclusive pricing. Pharmaceutical clinical trials exist when profit is possible at the end. For most peptides, that profit model does not work.
This does not make peptides ineffective. It makes them commercially unattractive to the entities that fund research at scale. The research that exists is largely from academic and international sources, much of it showing significant clinical promise. It simply has not been converted into FDA-approved drugs because nobody with the resources to do so has a financial incentive to complete that process.
BPC-157: The Gut and Beyond
BPC-157 stands for Body Protection Compound, and it is derived from a protein naturally found in gastric juice. The compound was identified through research into why the stomach is able to protect itself from the corrosive acid it produces. BPC-157 promotes angiogenesis (the growth of new blood vessels), modulates the healing response, and reduces inflammation in damaged tissue.
For gut applications, BPC-157 can be taken orally and remains active despite exposure to stomach acid, a significant advantage because most peptides are destroyed in the digestive tract. In oral form, it works locally on gut tissue, making it relevant for conditions like leaky gut, inflammatory bowel disease, and ulcers. The research on BPC-157’s gut protective effects is among the most robust in the peptide literature.
For musculoskeletal applications, tendon and ligament injuries in particular, BPC-157 is typically injected at or near the injury site. Animal studies show accelerated tendon healing and improved load tolerance after BPC-157 treatment. Human data is more limited but consistent with the animal models, and clinicians using it report outcomes that outpace what standard rehabilitation alone produces.
The compound also interacts with the dopaminergic and serotonergic systems, which is why some providers use it for mood support and neurological recovery applications. This neurotrophic activity expands the potential applications beyond physical tissue healing.
Source Quality Is the Critical Variable
The biggest risk in the peptide space is not the compounds themselves. It is the source.
There are two categories of peptide sources. Regulated compounding pharmacies operate under FDA oversight, require a prescription, formulate products to pharmaceutical standards, and test for purity and potency. Research-grade peptide suppliers are unregulated. They sell directly to consumers without a prescription, do not require medical supervision, and their purity and dosing accuracy are not verified by any external body.
Peptides purchased from research-grade suppliers may be impure, incorrectly dosed, or contain contaminants. This creates real risk, particularly for injectable applications where contaminants enter the bloodstream directly. Patients who have had negative experiences with peptides have often sourced them this way.
Working with a compounding pharmacy through a licensed provider is not just a legal formality. It is the only way to know that what you are injecting is what the label says it is.
Peptides as Messengers, Not Magic
One of the most important concepts for setting realistic expectations about peptide therapy is the messenger model. Peptides signal the body to do something. They do not do the thing themselves. They rely on the body’s own systems to carry out the response that the peptide triggers.
This has direct implications for who responds well and who does not. A person with foundational health problems, nutrient deficiencies, severe hormonal imbalance, significant gut dysfunction, cannot produce a strong response to a peptide signal because the systems being signaled are compromised. Peptides work best when they are layered on top of a functional foundation.
A person who is severely sleep-deprived, eating a highly processed diet, has unaddressed hormonal deficiencies, and starts a peptide protocol to accelerate tissue healing will see far less benefit than someone whose foundational health is in order. This is also why clinic-supervised peptide therapy tends to produce better results than self-administered protocols: the clinical context evaluates and addresses the foundation before adding targeted peptides.
Other Key Peptides and Their Applications
Beyond BPC-157, several other peptides have meaningful research supporting specific applications:
Thymosin Alpha-1 is derived from the thymus gland and stimulates T-cell production. It was used in Europe for hepatitis treatment for years and has been investigated for cancer adjunct therapy and immune system optimization. Patients with chronic infections or immune dysregulation are among those who may benefit most.
Selank is a synthetic peptide developed in Russia that modulates anxiety and cognitive function without the sedation or dependency risk of benzodiazepines. It affects brain-derived neurotrophic factor (BDNF) and modulates the stress response in ways that are meaningfully different from pharmaceutical anxiolytics.
SS-31 and MOTS-c target mitochondrial function. Mitochondria are the energy-producing structures in every cell, and their function declines with age and chronic stress. These peptides mimic the effects of exercise at the mitochondrial level, improving cellular energy production in ways that may not be achievable through exercise alone in significantly compromised systems.
The Receptor Burnout Problem
Continuous, uninterrupted stimulation of any receptor system produces adaptation. The receptor becomes less responsive over time, requiring higher doses for the same effect. This is true for pharmaceutical drugs and for peptides.
Effective peptide protocols incorporate cycling: periods of use followed by intentional breaks that allow receptor sensitivity to reset. This is not a difficult concept, but it requires clinical awareness. Self-directed protocols often ignore cycling because the user wants continuous effect and the feedback mechanism telling them to stop (diminishing returns) happens gradually enough that it goes unnoticed.
Receptor burnout is not dangerous in the same way as drug toxicity, but it reduces the therapeutic value of the protocol significantly. This is another reason why supervised protocols consistently outperform self-directed use.
The peptide field is advancing faster than medical education can incorporate it. The research base is growing. Providers who stay current on this literature are increasingly incorporating these tools into comprehensive treatment plans. The conversation is no longer whether peptides work. It is which ones, for which applications, through which sources, in what sequence. That is a clinical question, and it deserves a clinical answer.
About the Author: This article was written by the clinical education team at Med Matrix, a functional medicine clinic in South Portland, Maine. Med Matrix serves over 3,000 patients with a provider team that specializes in root-cause testing, hormone optimization, and personalized treatment plans.